Skip to search formSkip to main contentSkip to account menu

AM 4054

Known as: AM4054 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Despite a growing acceptance that withdrawal symptoms can emerge following discontinuation of cannabis products, especially in… 
2018
2018
AM6538 is a cannabinoid antagonist that binds CB1 receptors expressed in HEK-293 cells in a wash-resistant manner. The effects of… 
2016
2016
Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The… 
2014
2014
.....................................................................................................................................................................3 1. Background and Significance .............................................................................................................................4 1.1. The Cannabinoid System .................................................................................................................................4 1.1.1. History of Cannabinoids ...........................................................................................................................4 1.1.2. The Endocannabioid System ....................................................................................................................5 1.1.3. Cannabinoid Receptors .............................................................................................................................5 1.1.4. Pharmacology of CB drugs.......................................................................................................................6 1.1.5. Therapeutic Potential of Cannabinoids .....................................................................................................7 1.2. The Opioid System .....................................................................................................................................8 1.2.1. History of Opioids ....................................................................................................................................8 1.2.2. The Opioid System ...................................................................................................................................8 1.2.3. Clinical uses of opioids ............................................................................................................................9 1.3. Cannabinoids, Kappa Opioids and Diuresis ..................................................................................................10 2. Specific Aims ...................................................................................................................................................13 3. Materials and Methods .....................................................................................................................................14 3.1. Animals .........................................................................................................................................................14 3.2. Measurement of Diuresis ...............................................................................................................................14 3.3. Drugs .............................................................................................................................................................16 3.4. Statistical Methods ........................................................................................................................................17 4. Rationale, Research Strategy and Study Design ..............................................................................................18 4.1. Rationale ........................................................................................................................................................18 4.2. Research Strategy ..........................................................................................................................................18 4.3. Study Design .................................................................................................................................................19 5. Results ..............................................................................................................................................................20 5.1. Validating Cannabinoid mediated diuresis in mice .......................................................................................20 5.2. Validating Kappa Opioid mediated diuresis in mice .....................................................................................22 5.3. Effects of Chronic THC dosing on the diuretic dose response of the CB1 agonist, AM4054 ......................24 5.4. Effects of Chronic THC dosing on the diuretic dose response of the kappa opioid, U50488 .......................27 5.5. Effects of Chronic THC dosing on diuretic dose response of furosemide ....................................................31 6. Discussion.........................................................................................................................................................33 7. Conclusions ......................................................................................................................................................37 8. Bibliography .....................................................................................................................................................38 
2013
2013
In vivo effects of cannabinoid (CB) agonists are often assessed using four well-established measures: locomotor activity… 
2013
2013
The effects of cannabinoid CB1 agonists (including Δ9-tetrahydrocannabinol, the main psychoactive component of marijuana) on… 
2008
2008
Discriminative‐stimulus (Sd) properties of cannabinergic (CB) ligands other than the CB‐1 partial agonist Δ9–THC have not been…